 | Up a level |
Horn, Michael P; Zuercher, Adrian W; Imboden, Martin A; Rudolf, Michael P; Lazar, Hedvika; Wu, Hong; Hoiby, Niels; Fas, Stefanie C; Lang, Alois B (2010). Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrobial agents and chemotherapy, 54(6), pp. 2338-44. Washington, D.C.: American Society for Microbiology 10.1128/AAC.01142-09
Lazar, Hedvika; Horn, Michael P; Zuercher, Adrian W; Imboden, Martin A; Durrer, Peter; Seiberling, Michael; Pokorny, Rolf; Hammer, Christophe; Lang, Alois B (2009). Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrobial agents and chemotherapy, 53(8), pp. 3442-6. Washington, D.C.: American Society for Microbiology 10.1128/AAC.01699-08
Zuercher, Adrian W; Horn, Michael P; Que, John U; Ruedeberg, Anna; Schoeni, Martin H; Schaad, Urs B; Marcus, Paul; Lang, Alois B (2006). Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS immunology and medical microbiology, 47(2), pp. 302-8. Oxford: Blackwell 10.1111/j.1574-695X.2006.00103.x
Lang, Alois B; Rüdeberg, Anna; Schöni, Martin H; Que, John U; Fürer, Emil; Schaad, Urs B (2004). Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatric infectious disease journal, 23(6), pp. 504-10. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.inf.0000129688.50588.ac
